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Cry5B crystal protein 
A B S T R A C T   
Ascaris and Parascaris are important parasites in the family Ascarididae, large, ubiquitous intestinal-dwelling 
nematodes infecting all classes of vertebrates. Parasitic nematode drug resistance in veterinary medicine and 
drug recalcitrance in human medicine are increasing worldwide, with few if any new therapeutic classes on the 
horizon. Some of these parasites are zoonotic, e.g., Ascaris is passed from humans to pigs and vice versa. The 
development of new therapies against this family of parasites would have major implications for both human and 
livestock health. Here we tested the therapeutic ability of a paraprobiotic or dead probiotic that expresses the 
Bacillus thuringiensis Cry5B protein with known anthelmintic properties, against zoonotic Ascaris suum and 
Parascaris spp. This paraprobiotic, known as IBaCC, intoxicated A. suum larvae in vitro and was highly effective in 
vivo against intestinal A. suum infections in a new mouse model for this parasite. Fermentation was scaled up to 
350 l to treat pigs and horses. Single dose Cry5B IBaCC nearly completely cleared A. suum infections in pigs. 
Furthermore, single dose Cry5B IBaCC drove fecal egg counts in Parascaris-infected foals to zero, showing at least 
parity with, and potential superiority to, current efficacy of anthelmintics used against this parasite. Cry5B IBaCC 
therefore represents a new, paraprobiotic One Health approach towards targeting Ascarididae that is safe, 
effective, massively scalable, stable, and useful in human and veterinary medicine in both the developed and 
developing regions of the world.   
1. Introduction 
Ascaris lumbricoides or the large intestinal roundworm is the most 
common nematode parasite of humans, infecting approximately 1 
billion people in mostly tropical and subtropical countries [1,2]. These 
gastrointestinal nematode (GIN) parasites live in the small intestine, 
reaching more than 30 cm in length. Recent nuclear genome studies 
indicated that A. lumbricoides and Ascaris suum, the ubiquitous and 
important Ascaris parasite of pigs, are highly interbred [3]. Indeed, 
A. suum is a zoonosis that can express as a haplotype of A. lumbricoides, 
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with each parasite species able to infect both pigs and humans [3–8]. In 
the same family (Ascarididae) and closely related to these Ascaris par-
asites is Parascaris spp., the omnipresent parasite of foals and young 
horses around the world that has developed multi-drug resistance, with 
increasing concern [9]. Ascaris and Ascaris-related parasites are impor-
tant components of the “One Health” concept [3,10,11]. 
Infestation in humans with Ascaris is responsible for an estimated 
loss of 1–1.5 million disability adjusted life-years (DALYs) and for 
60,000–200,000 deaths yearly due to obstruction of the digestive tract 
and hepatobiliary and pancreatic ascariasis, the true impact of which 
has likely been underestimated [1,2,12]. Infection rates can be very high 
in places, e.g., reaching >50% prevalence in six states in India covering 
nearly 30% of the total population of India and > 44% prevalence in a 
systematic meta-analysis of studies conducted in Nigerian children 
[13,14]. Acute symptoms due to adult parasites inhabiting the gastro-
intestinal (GI) tract include abdominal pain, bloating, nausea, vomiting, 
anorexia, and intermittent diarrhea (with heavy loads leading to serious 
complications and even death). However, the more significant impact is 
in children who are more susceptible to these parasites. The conse-
quences of long-term infestation includes malabsorption of nutrients, 
protein energy malnutrition, and reduced food intake, leading to growth 
retardation, negative impacts on cognitive development, school absen-
teeism, and reduced economic productivity [1,2,8,15]. 
Although single dose anthelmintic cure rates against A. lumbricoides 
are reported to be >90% [8], there are numerous reports in the literature 
of deficiencies in treating this parasite with benzimidazoles (anthel-
mintic of choice for Mass Drug Administration or MDA). These diffi-
culties include lower than expected cure rates with albendazole in Africa 
and Asia (0%, 19%, 41%, and 56% in four separate studies; [16–19]) 
and strong persistence of this parasite in African, Asian, and Central 
American countries despite consistent annual deworming campaigns 
spanning multiple years [20–25]. Known benzimidazole resistance al-
leles have been detected in natural populations of Ascaris, although 
there is evidence that resistance/recalcitrance may occur without these 
alleles [19,21,26]. Although ivermectin can also be used against this 
parasite, annual MDA incorporating both albendazole and ivermectin 
has failed to eliminate it, resulting in only modest prevalence reductions 
[27]. 
As noted above, ascarids closely related to A. lumbricoides are also 
common and important parasites of livestock and companion animals. 
Ascaris suum is a common production and health problem in pigs 
worldwide because of poor feed utilization and liver condemnation at 
slaughter where different stringencies of management fail to eliminate 
infection rates even in large global producing countries [28]. Recent 
A. suum prevalence surveys in the United States are lacking but routine 
deworming strategies are used in >77% of production facilities for 
breeding age pigs and at >17% and > 14% for nursery and grower/ 
finisher pigs, respectively [29], indicating a need for practical and 
effective anthelmintic formulations in the market-place. Parascaris spp. 
are the most important parasites of foals and young horses around the 
world [9]. The parasites are truly ubiquitous and virtually every foal 
should be considered exposed. Equine ascarids cause small intestinal 
impaction when a cluster of worms block the intestinal lumen. This is a 
painful and life-threatening condition, and even with successful 
abdominal surgery, the prognosis for long-term survival is guarded to 
poor [9]. This is concerning as Parascaris spp. are found widely resistant 
to currently available anthelmintic drug classes, most notably to the 
most widely used drug class, the macrocyclic lactones [30]. The phar-
maceutical industry has developed and introduced very few new 
anthelmintic drug classes and none for equine use since the early 1980s, 
and research exploring alternative treatment modalities is urgently 
needed. There is real concern that Ascaris spp. could also (indepen-
dently) develop widespread drug resistance that is now observed in 
closely related Parascaris spp. Taken together, these findings all point to 
the urgency and importance of developing new anthelmintic formula-
tions for treating Ascaris and Parascaris parasites of humans, livestock, 
and companion animals. 
Continuing human MDA campaigns and veterinary parasite control 
strategies would therefore benefit substantially with the addition of new 
anthelmintics against ascarid parasites with the following requirements: 
highly and broadly potent against this family of helminths, and safe, 
inexpensive, and massively scalable for MDA. We have recently 
described an active pharmaceutical ingredient (API) called IBaCC (see 
below) containing the Bacillus thuringiensis (Bt) Crystal (Cry) protein 
Cry5B that is effective against human hookworm infections in rodents 
and against Haemonchus contortus infections in sheep and that meets all 
the requirements for MDA [31,32]. Cry5B itself was shown to be active 
against A. suum in pigs when delivered as a live spore-crystal lysate 
(SCL) [33]. However, delivery of SCL or of live bacteria in general is not 
ideal for MDA because of an unstable shelf life, environmental concerns, 
potential safety/regulatory issues, and development of resistance via 
suboptimal dosing [31,34–38]. Here, for the first time, we describe and 
test Cry5B IBaCC against Ascaris infection in pigs and Cry5B itself (as 
IBaCC) for the first time against Parascaris infection in horses. 
2. Materials and methods 
2.1. Animal ethics and approvals 
All protocols in the study were approved by the University of Ken-
tucky Institutional Animal Care and Use Committee (Protocol 
2015–2078) for the equine studies and the USDA Beltsville - Institutional 
Animal Care and Use Committee #18–008, #18–029 and #17–019 for 
use of mice and pigs, respectively, and Institutional Biosafety Committee 
#271. 
2.2. Preparation of Cry5B IBaCC and in vitro studies 
Cry5B IBaCC was prepared as described [31]. Briefly, spo0A- 
B. thuringiensis cells expressing Cry5B from a vegetative promoter were 
cultured in 3× LB for 48 h, resuspended in 1/2 volume, treated with 
essential oil, and then washed. All Cry5B IBaCC used in this study was 
prepared at the Synthetic Biomanufacturing Facility, Utah State Uni-
versity, at a scale of 350 l. Cry5B concentration was quantitated relative 
to BSA standards by SDS PAGE densitometry. 
Ascaris suum fourth staged larval (L4) parasites were isolated from 
the small intestines of B6/STAT6KO mice ~12 days post-inoculation (P. 
I.) and shipped overnight to the Aroian laboratory from the Urban lab-
oratory in Beltsville, MD. The next day, the parasites were subjected to in 
vitro testing with Cry5B IBaCC at two doses and buffer control using the 
same protocol for setting up and scoring Ascaris larval in vitro [33,39]. In 
each experiment, each condition contained two wells with five larvae 
per well. Simply, larvae that moved either on their own or upon 
touching with a needle were scored as alive and larvae that failed to 
move even after touching were scored as dead [33,39]. The experiment 
was repeated twice with two different batches of larvae and two 
different batches of Cry5B IBaCC. A separate experiment was performed 
in which IBa (Inactivated Bacterium with empty vector, identical and 
identically processed to IBaCC in every way except that the vector does 
not contain a Cry5B insert) was matched in optical density (OD600) to 
100 μg/mL IBaCC and tested against A. suum L4 parasites in two inde-
pendent experiments (n = 20 larvae total). Incubation with IBa resulted 
in 100% viability (20/20) of A. suum L4 up to and including 96 h 
incubation. 
2.3. Mouse Ascaris in vivo experiment 
Breeding pairs of C57BL/6(B6)-STAT6KO were originally procured 
from the Jackson Laboratories, Bar Harbor, ME and bred at the USDA/ 
ARS/Beltsville Agricultural Research Center in Beltsville, MD. Groups of 
five mice each containing both males and females were inoculated per os 
with 10,000 infective A. suum eggs and 12 days later were 1) untreated, 
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2) treated per os with IBaCC containing Cry5B at 6 mg/kg body weight, 
or 3) treated per os with IBaCC containing Cry5B at 20 mg/kg body 
weight. Those in group 3 received a second dose of IBaCC containing 
Cry5B at 20 mg/kg body weight on the next day. A. suum L4 were iso-
lated from the small intestines six days later by opening the small in-
testine with scissors and placing them above a tea strainer submerged in 
100 ml of phosphate-buffered saline (PBS) maintained for 3 h at 37C in a 
water bath. The L4 falling to the bottom of the beaker containing the PBS 
were then placed in a line-grated rectangular culture dish and counted 
using a dissecting microscope; larvae were identified morphologically as 
L4 [40]. These mice were also inoculated with infective Heligmosomoides 
polygyrus bakeri third-stage larvae and infective Trichuris muris eggs to 
test Cry5B IBaCC efficacy against multiple nematode infections in a 
single mouse host. The results of IBaCC treatment on these other para-
sites will be presented in a separate report. 
2.4. Pig Ascaris in vivo experiment 
Experimental pigs were obtained from the facility at the Beltsville 
Agricultural Research Center, Beltsville, MD and were housed and 
managed as previously described [33]. The pigs were mixed sex and 
approximately 8 weeks of age with each group containing six pigs at the 
time of per os inoculation with 10,000 infective A. suum eggs [33]. Pigs 
were treated per os 12 days after parasite egg inoculation with a single 
dose of IBaCC at 30 mg/kg Cry5B body weight (treated group) or a 
vehicle control (control group) and euthanized four days later to recover 
A. suum L4 from the small intestine [33]. The L4 isolated from an agar- 
gel matrix of intestinal contents were counted using a dissecting mi-
croscope to determine the number of morphologically identified L4 [40] 
per pig. 
2.5. Horse Parascaris spp. experiment 
Ten horse foals born on the University of Kentucky Research Farm in 
2019 were enrolled in the study. The foals were exposed to parasites on 
contaminated pasture to become naturally infected with Parascaris spp. 
and did not receive anthelmintic treatment prior to the study. From 
three months of age, the foals were examined for ascarid fecal egg counts 
determined in triplicate with the Mini-FLOTAC method as previously 
described [41] . Once foals exceeded 100 ascarid eggs per gram (EPG), 
they were ranked by egg count magnitude and blocked into pairs of two. 
From these blocks, foals were randomly allocated to either treatment or 
control group. Foals in the treatment group were administered a single 
dose of Cry5B IBaCC at 30 mg/kg via nasogastric tube. Foals in the 
control group were kept untreated. Egg counts were determined on the 
day of treatment and weekly for four weeks post treatment. 
2.6. Statistical methods 
Prism v.8 was used for all graphs and comparisons. The comparison 
of fecal egg counts in the foal study was carried out using two-way 
analysis of variance (mixed-effects analysis Time x Treatment). For the 
in vivo mouse experiment, one-way analysis of variance (ANOVA) with 
Dunnett’s post-test was used relative to water control. For comparisons 
including just two groups in the pig study and the end of the horse study, 
a one-tailed Mann-Whitney (non-parametric) test was used with the 
assumption that treatment reduced parasite burdens or fecal egg counts. 
For the comparison of fecal egg counts at the beginning of the horse 
study, a two-tailed Mann-Whitney test was used to test for equivalence 
of starting fecal egg counts. 
3. Results 
3.1. Cry5B IBaCC intoxicates A. suum intestinal fourth larval stage in 
vitro 
Bt Cry5B is a potent anthelmintic protein that has been studied in vivo 
against hookworms in rodents/dogs and Ascaris infections in pigs 
delivered as spore crystal lysates or as protein isolated from spore crystal 
lysates, neither of which are compatible with scale up technologies or 
broadly effective drug distribution strategies [31,33,42–46]. IBaCC or 
Inactivated Bacterium with Cytosolic Crystal is an API form compatible 
with MDA in which Bt Cry protein crystals are produced in the cytosol of 
asporagenous Bt, that is subsequently killed or inactivated by incubation 
in food-grade essential oil [31]. IBaCC is effective against hookworm 
infections in rodents and Haemonchus infections in ruminants (Li et al. 
2020; Sanders et al. 2020). A dead probiotic with therapeutic benefit is 
known as a paraprobiotic [37]. 
How IBaCC would interact with ascarids, which have different 
mouth parts, feeding patterns, food sources, and behaviors than hook-
worms, was unknown. IBaCC containing Cry5B (or Cry5B IBaCC) was 
initially tested against intestinal A. suum fourth stage larvae (L4s) using 
a new protocol for isolation from immune deficient mice and incubated 
in vitro with IBaCC containing two different Cry5B doses. Visible changes 
in the L4 treated with Cry5B IBaCC relative to buffer control were seen 
(e.g., paler coloration, degenerated intestinal appearance, rigidity in 
shape, and reduced movement), indicating clear intoxication of A. suum 
by Cry5B IBaCC (Fig. 1A). Intoxication was quantitatively evident at 10 
μg/mL and more strongly at 100 μg/mL Cry5B content, with near 
complete death/immobilization seen at 100 μg/mL (~700 nmolar) at 
48 h (Fig. 1B). As has been shown with all other parasitic nematodes 
tested [31,47], intoxication of A. suum by Cry5B IBaCC was dependent 
upon Cry5B protein since incubation of parasites in the presence of IBa 
control lacking Cry5B but otherwise identical to IBaCC resulted in no 
intoxication (detailed in Materials and Methods). These in vitro data 
indicated that Cry5B IBaCC, but not the inactivated bacterium 
B. thuringiensis with empty vector (IBa), has potential to impact A. suum 
infections in vivo. 
3.2. Cry5B IBaCC has a significant impact on intestinal A. suum intestinal 
infections in mice and pigs 
Before testing in large animals, we tested Cry5B IBaCC against in-
testinal A. suum infections in mice. We have found that C57BL/6(B6)- 
STAT6KO mice support the development of A. suum to the L4 intesti-
nal stage, at which point they are expelled (~day 20 post-inoculation or 
P.I.). B6/STAT6KO mice were inoculated per os with A. suum eggs. 
Twelve days P.I., the mice (n = 5 per group) were treated with either 
water (control), IBaCC at 6 mg Cry5B/kg by body weight, or IBaCC at 20 
mg Cry5B/kg body weight. Those mice that received 20 mg/kg received 
a second 20 mg/kg body weight dose day 13 P.I. This double 20 mg/kg 
dose mimics what was done in the published pig study using Cry5B SCL 
[33]. Five days later small intestinal worm burdens were determined. 
Treatment with two 20 mg/kg doses resulted in a statistically significant 
92.5% reduction in intestinal worm burdens relative to control (Fig. 2), 
similar to what was seen in pigs using SCL and the same dosing regimen 
[33]. Treatment using a single 6 mg/kg body weight of Cry5B in IBaCC 
also resulted in a significant 62% reduction in intestinal A. suum L4 
burdens (Fig. 2). These results in mice with a TH2-immune deficient 
background further reinforce previous findings that Cry5B efficacy is 
due to a direct impact on parasites and is not dependent upon an intact 
immune response [44]. 
Based on in vitro data and in vivo efficacy in the mouse model, Cry5B 
IBaCC production was scaled up to 350 l at a contract manufacturing 
organization (CMO) for studies in large animals [31]. Twelve pigs were 
inoculated per os with A. suum eggs. Based on success with single dosing 
in mice, a single-dose treatment trial was performed. Twelve days P.I., 
J.F. Urban Jr et al.                                                                                                                                                                                                                             
One Health 12 (2021) 100241
4
six pigs were left untreated and six pigs were given per os a single dose of 
IBaCC at a dose of 30 mg Cry5B/kg body weight. Four days later, in-
testinal worm counts were determined for all pigs. As shown (Fig. 3), 
single dose Cry5B IBaCC resulted in a statistically significant reduction 
and near complete clearance of A. suum L4 from the pig intestine (96% 
reduction relative to control). 
3.3. Cry5B IBaCC clears fecal egg counts in horses infected with the 
related parasite Parascaris spp 
Parascaris infection is deleterious to equines (foals) and is phyloge-
netically related to A. suum and A. lumbricoides [48,49]. As scaled-up 
IBaCC effectively cleared A. suum infections in pigs at a single dose of 
30 mg Cry5B/kg body weight, we similarly tested a single dose of IBaCC 
at 30 mg Cry5B/kg body weight against adult Parascaris spp. infections 
in naturally infected foals. 
Ten foals were selected via rolling enrollment in control (n = 4) and 
Cry5B IBaCC treatment arms (n = 6). Each foal in the treatment arm was 
administered via naso-gastric tube a single dose of 30 mg/kg Cry5B in 
IBaCC produced at 350 l scale by a CMO. Fecal egg counts were deter-
mined on the day of treatment and then once weekly for 4 weeks. The 
results are shown in Fig. 4. Fecal egg counts in foals from both the 
control and treatment arms were statistically similar at the beginning of 
the study, with mean ascarid egg counts of 916 and 673 eggs per gram of 
feces, respectively. Fecal egg counts persisted in all foals in the control 
group up until and including day 14 and in three out of four foals 
throughout the entire duration of the study. In contrast, fecal egg counts 
went to zero in all Cry5B IBaCC-treated foals at the first sample taken 
one-week post-treatment and stayed at zero for all treated foals 
throughout the study. Two-way analysis of variance showed a statisti-
cally significant difference between control and treatment arms. A sig-
nificant difference in fecal egg counts at each time point post-treatment 
was also seen (shown for the final time point; Fig. 4). These data indi-
cated that Cry5B IBaCC had a dramatic impact on Parascaris infections in 
foals. 
4. Discussion 
Ascarid parasites are some of the most common and damaging 
Fig. 1. Cry5B IBaCC intoxicates A. suum in vitro. A) 
Image of A. suum fourth-stage larvae (L4) in the pres-
ence of 100 μg/mL Cry5B in IBaCC or absence of Cry5B 
IBaCC. Intoxicated larvae were straightened and 
immobile. Healthy larvae had multiple bends and were 
motile. Images were taken at 48 h. B) Percent of 
A. suum larvae alive over time in vitro at two doses of 
Cry5B in IBaCC relative to control (buffer only). Shown 
is the average and standard error of two independent 
experiments with two wells per experiment (5 larvae 
per well).   
Fig. 2. Cry5B IBaCC is efficacious against A. suum L4 intestinal stage in mice. 
Shown are the parasite burdens from B6/STAT6KO mice inoculated with 
infective A. suum eggs and treated with water, single dose Cry5B IBaCC (6 mg/ 
kg body weight), or double dose Cry5B IBaCC (2 × 20 mg/kg body weight). 
Statistical comparisons of treated groups relative to water control are shown. 
Long bar for each treatment is mean; short bars indicate standard error. 
Fig. 3. Cry5B IBaCC is highly effective against A. suum L4 intestinal stage in-
fections in pigs. Shown are the average parasite burdens in pigs given water or 
single dose Cry5B IBaCC at 30 mg/kg body weight. Error bars indicate stan-
dard error. 
Fig. 4. Cry5B IBaCC is highly effective against Parascaris spp. Infections in 
foals. Shown are the average fecal egg counts over time; error bars indicate 
standard error. Day 0 fecal egg counts were taken before the first treatment. The 
difference between fecal egg counts between control and foals treated with 
IBaCC at 30 mg/kg Cry5B body weight based on two-way analysis of variance 
was significant (P = 0.0074). P values shown indicate the comparison between 
fecal egg counts in treated and control groups before treatment (day 0; P =
0.91) and at the last data point taken (day 28; P = 0.033). 
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parasites of humans and animals on earth. In veterinary medicine, the 
recalcitrance of Parascaris to treatment and development to resistance is 
well documented. Although Ascaris infections in humans are considered 
well managed with current therapeutics, a detailed look at the efficacy 
data and the propensity for livestock to develop anthelmintic resistance 
from intensive drug treatment is foreboding for MDA strategies in 
humans (see Introduction). Therefore, new therapies against this class of 
parasite in the pipeline are urgently needed and would play an impor-
tant role in promoting One Health. However, to be therapeutically 
deployable in both human and veterinary medicine in the developed and 
developing world, such therapies need to be safe, broadly active against 
this class of parasite, inexpensive, and massively scalable. We are un-
aware of any new drugs that meet these criteria that are in the com-
mercial pipeline. 
Here we demonstrated that Cry5B IBaCC, a recombinant parapro-
biotic (dead bacterial ghost) containing an active Bt Cry protein crystal, 
has great promise to fulfill this void. Single-dose Cry5B IBaCC is effective 
against two ascarid species in vivo in three different mammalian hosts. In 
mice and pigs, Cry5B IBaCC was effective at near complete elimination 
of A. suum parasite burdens in the small intestine. In horses, Cry5B 
IBaCC completely eliminated parasite fecal egg counts. Important future 
studies in horses would include determination of intestinal parasite 
burdens in control versus Cry5B IBaCC-treated foals. Because A. suum 
and A. lumbricoides are very closely related parasites and because the pig 
GI tract is considered a good model for the human GI tract, the data 
suggest that Cry5B IBaCC will be highly effective against A. lumbricoides 
infections in humans. Important future studies would also include 
testing this hypothesis. 
Cry5B IBaCC production was scaled up for these large animal studies 
to 350 l scale at a CMO. Crystal proteins as part of live spore crystal 
lysates are massively and cheaply produced around the world to control 
insect pests, paving the way for comparable production levels of Cry5B 
IBaCC. However, the therapeutic application of live spore crystal lysates 
or live bacteria in general is not desirable for humans and other animals 
because of potential safety issues, environmental contamination, repli-
cation in soil and intestines leading to increased risk of parasite resis-
tance, instability of live bacteria on the shelf, and the relationship 
between B. thuringiensis and Bacillus cereus [31]. Cry5B IBaCC alleviates 
all these disadvantages while retaining all the advantages of scalability 
and safety of Cry proteins themselves. The production process of Cry5B 
IBaCC itself is simple and transferable [31]. Moreover, a pilot toxicology 
study in hamsters demonstrated that five consecutive daily doses of 
IBaCC at 200 mg Cry5B/kg body weight was completely safe and non- 
toxic based on no deviation from normal histopathology and blood 
chemistry [31]. Good laboratory practice (GLP) toxicological studies 
with larger-sized study groups and clinical-grade materials are planned 
for the near future. 
Notably, the development of anthelmintic resistance to Cry5B was 
found to be relatively more difficult than to a benzimidazole and a 
nicotinic acetylcholine receptor (nAChR) agonist based on forward ge-
netic screens in Caenorhabditis elegans [50]. Furthermore, nematodes 
resistant to nAChR agonist anthelmintics were hyper-susceptible to 
Cry5B, and Cry5B and nAChR agonists (e.g., pyrantel and tribendimi-
dine) were synergistically more efficacious in vitro and in vivo against 
free-living and parasitic nematodes [43,50]. These properties (hyper- 
susceptibility and synergy) are predictive of combination drug therapies 
recalcitrant to the development of resistance. 
5. Conclusions 
Our data indicate that Cry5B IBaCC can make a significant contri-
bution to the long-term, safe, and effective control of ascarid parasites of 
humans and other animals. The scalability, adaptability, safety, and ease 
of manufacture of Cry5B IBaCC make it ideally suited for promoting One 
Health against ascarid parasites equally in humans and livestock in 
developed and developing countries. The research reported here more 
generally points towards the suitability and great potential of parapro-
biotics to treat pathogens of humans and livestock, that is also likely to 
include ascarids of companion animals such as dogs and cats. Devel-
opment of a common delivery system of paraprobiotic formulations for 
cures for both humans and animals promotes the concept of One Health. 
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